Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

Sébastien Le Burel, Stéphane Champiat, Christine Mateus, Aurélien Marabelle, Jean Marie Michot, Caroline Robert, Rakiba Belkhir, Jean Charles Soria, Salim Laghouati, Anne Laure Voisin, Olivier Fain, Arsène Mékinian, Laetitia Coutte, Tali Anne Szwebel, Laetitia Dunogeant, Bertrand Lioger, Cécile Luxembourger, Xavier Mariette, Olivier Lambotte

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    152 Citations (Scopus)

    Résumé

    Aim The growing use of immune checkpoint inhibitors (ICIs) is associated with the occurrence of immune-related adverse events (irAEs). Few data are published on systemic, immunohaematological and rheumatic irAEs. In a pharmacovigilance database analysis, we screened for these irAEs and calculated their prevalence.

    langue originaleAnglais
    Pages (de - à)34-44
    Nombre de pages11
    journalEuropean Journal of Cancer
    Volume82
    Les DOIs
    étatPublié - 1 sept. 2017

    Contient cette citation